Impurities regulatory guidance

Regulatory guidance is provided in Chapter 2, which includes a significant discussion on ICH guidelines. Thresholds for identification, safely qualification, and reporting impurities have been set in these guidelines with... 

S., Patel, Hasmukh B., Powers, Roslyn F., and Yu, Lawrence, Pharmaceutical impurities regulatory perspective for abbreviated new drug apphcations. Advanced Drug Delivery Reviews, 59, 64—72, 2007. Guidance issued by the EMEA (European Medicines Agency, Evaluation of Medicines for Human Use, London, June 23, 2004. See also Reference 6. 

The following definition of impurity is currently under consideration by the regulatory bodies, which is likely to be included in the future guidance 4... 

The extent of validation required will depend on the nature of the intended analytical outcomes. Is the method quantitative (i.e., to allow a measure of quantity of some characteristic of the sample, whether it be active ingredient, impurities, or excipient) or is the method simply a determination of what is present (qualitative) In the forensic environment, both qualitative and quantitative data will most likely be required therefore, it is advisable to ensure that the validation covers both aspects. The extent to which validation is conducted and the parameters that should be included have been the subject of several guidance documents produced by a variety of industrial committees and regulatory or advisory bodies. 

---